EUVIMEDEUVIMED entdecken
Crossref

Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome

An Chen, Zirong Lan, Li Li, Luting Xie, Xiaoyu Liu, Xiulin Yang, Siyi Wang, Qingchun Liang, Qianqian Dong, Liyun Feng, Yining Li, Yuanzhi Ye und 3 weitere

Cardiovascular Research · 24.10.2023 · 119 (13) · 2368-2381

DOI: 10.1093/cvr/cvad119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 31.07.2023. Verfasst von An Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou,…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Vascular Calcification, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 64-mal zitiert (Crossref). Gefördert von: National Natural Science Foundation of China, Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Vascular calcification (VC) is prevalent in pathological processes such as diabetes, chronic kidney disease (CKD), and atherosclerosis, but effective therapies are still lacking by far. Canagliflozin (CANA), a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes mellitus and exhibits beneficial effects against cardiovascular disease. However, the effect of CANA on VC remains unknown. In this study, we hypothesize that CANA protects against VC. Methods and results Micro-computed tomography analysis and alizarin red staining revealed that CANA treatment prevented aortic calcification in CKD rats and in VitD3-overloaded mice. Moreover, CANA alleviated the calcification of rat and human arterial rings. Alizarin red staining revealed that calcification of rat and human vascular smooth muscle cells (VSMCs) was attenuated by CANA treatment and this phenomenon was confirmed by calcium content assay. In addition, CANA downregulated the expression of osteogenic differentiation markers Runx2 and BMP2. Of interest, qPCR and western blot analysis revealed that CANA downregulated the expression of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and the downstream signalling molecules Caspase-1 and IL-1β in VSMCs as well. Both NLRP3 inhibitor MCC950 and knockdown of NLRP3 by siRNA independently resulted in decreased calcification of VSMCs. By contrast, activation of NLRP3 exacerbated VSMC calcification, and this effect was prevented by the addition of CANA.

Conclusions

Our study for the first time demonstrates that CANA exerts a protective effect on VC at least partially via suppressing the NLRP3 signalling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for VC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Vascular CalcificationRenal Insufficiency, ChronicRatsHumansMiceAnimalsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinCanagliflozinLeucineOsteogenesisPyrin DomainX-Ray MicrotomographyGlucoseNucleotidesSodiumMyocytes, Smooth MuscleAnthraquinones

Stichwörter der Autor:innen

CanagliflozinChronic kidney diseaseNLRP3Vascular calcificationVascular smooth muscle cell

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinCanagliflozinLeucineGlucoseNucleotidesSodiumalizarinAnthraquinones

Autor:innen und Institutionen

  • Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510280, China.
  • Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, 253 Industrial Avenue, Guangzhou, 510280,…
  • Department of Cardiology, Guangzhou Red Cross Hospital, Jinan University, 396 Tongfu Middle Road, Guangzhou, 510220, China.
  • Department of Anesthesiology, The Third Affiliated Hospital, Southern Medical University, 183 West Zhongshan Avenue, Guangzhou, 510630, China.
  • Department of Pathophysiolgy, Zhongshan Medical School, Sun Yat-Sen University, 74 Zhongshan Er Road, Guangzhou, 510080, China.

ORCID-Profile: Jianyun Yan

Förderung

  • National Natural Science Foundation of China
  • Research Foundation

Zitieren

APA

Chen, A., Lan, Z., Li, L., Xie, L., Liu, X., Yang, X., Wang, S., Liang, Q., Dong, Q., Feng, L., Li, Y., Ye, Y., Fu, M., Lu, L., & Yan, J. (2023). Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome. Cardiovascular Research, 119(13), 2368-2381. https://doi.org/10.1093/cvr/cvad119

Vancouver

Chen A, Lan Z, Li L, Xie L, Liu X, Yang X, et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome. Cardiovascular Research. 2023;119(13):2368-2381. doi:10.1093/cvr/cvad119

BibTeX
@article{Chen2023,
  author = {Chen, An and Lan, Zirong and Li, Li and Xie, Luting and Liu, Xiaoyu and Yang, Xiulin and Wang, Siyi and Liang, Qingchun and Dong, Qianqian and Feng, Liyun and Li, Yining and Ye, Yuanzhi and Fu, Mingwei and Lu, Lihe and Yan, Jianyun},
  title = {Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {119},
  number = {13},
  pages = {2368--2381},
  doi = {10.1093/cvr/cvad119}
}
Kostenlos starten →